AZD1236, an existing drug used primarily for the treatment of COPD, reduces damage following spinal cord injury by inhibiting the inflammatory response in the spinal cord.
Gene therapy that inhibits targeted nerve cell signals effectively improves symptoms of neuropathic pain without negative side effects in mouse models of spinal cord injury or peripheral nerve damage.
An innovative new system that includes electronic implants directly onto the spinal cord reactivates neurons that control blood pressure, allowing a patient with multiple system atrophy-parkinsonian type (MSA-P) to retain consciousness when she is in an upright position.
Researchers have successfully stabilized an enzyme that is able to degrade scar tissue as a result of spinal cord injury with the help of AI and robotics.
Researchers engineered functional human spinal cord tissue from cells and human materials which, when implanted into animal models of spinal cord injury, restored walking ability in 80% of the test subjects.
Harnessing the power of "dancing molecules", researchers have developed a new injectable therapy that repairs tissue damage and reverses paralysis in mouse models. Within four weeks of receiving the injection, paralyzed mice regained the ability to walk.
Fenofibrate, an FDA-approved drug commonly used to treat high cholesterol, activated support cells around sensory neurons in mouse models of spinal cord injury, helping them regrow twice as fast as a placebo.
Exoskeletons that help those with spinal cord injuries to walk may help to improve bowel function.
A newly developed hydrogel scaffold with regularly spaced pores assists in spinal cell growth and neuron regeneration following spinal cord injury.
Researchers modified NG2 glial cells in the central nervous system into new neurons to promote recovery following spinal cord injury.
Both the ApoE genotype and the sex of the mouse impacted the manner in which the animals with spinal cord injury responded to hypoxia treatment. Females with the ApoE e4 gene had a negative response to intermittent hypoxia.
Injecting a patient's own bone marrow derived stem cells significantly improved motor function within weeks in those with spinal cord injuries.
